OASMY (Vivesto AB) Cyclically Adjusted Revenue per Share: $0.00 (As of Mar. 2026)


OASMY Vivesto AB OASMY
26 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Vivesto AB Cyclically Adjusted Revenue per Share?

Vivesto AB OASMY 26 Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vivesto AB's adjusted revenue per share for the three months ended in Mar. 2026 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vivesto AB was -9.90% per year. The lowest was -9.90% per year. And the median was -9.90% per year.

As of today (2026-07-08), Vivesto AB's current stock price is $0.0001. Vivesto AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.00. Vivesto AB's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivesto AB was 324.28. The lowest was 4.67. And the median was 49.64.


Vivesto AB  (OTCPK:OASMY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivesto AB was 324.28. The lowest was 4.67. And the median was 49.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vivesto AB Cyclically Adjusted Revenue per Share Related Terms


Vivesto AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vivesto AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB Cyclically Adjusted Revenue per Share Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.00 0.00 0.00 0.00

Vivesto AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OASMY vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Cyclically Adjusted PS Ratio falls into.


OASMY
26GF Score
Vivesto AB OASMY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vivesto AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/133.5600*133.5600
=0.000

Current CPI (Mar. 2026) = 133.5600.

Vivesto AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201604 0.000 100.732 0.000
201607 0.000 101.080 0.000
201610 0.000 101.485 0.000
201701 0.000 101.326 0.000
201704 0.000 102.615 0.000
201707 0.000 103.301 0.000
201710 0.002 103.202 0.003
201801 0.001 102.925 0.001
201804 0.001 104.390 0.001
201807 0.000 105.420 0.000
201810 0.000 105.545 0.000
201901 0.001 104.855 0.001
201904 0.000 106.627 0.000
201907 0.000 107.166 0.000
201910 0.000 107.243 0.000
202001 0.000 106.215 0.000
202004 0.117 106.240 0.147
202007 0.000 107.731 0.000
202010 0.000 107.539 0.000
202103 0.000 108.360 0.000
202106 0.003 108.928 0.004
202109 0.008 110.338 0.010
202112 0.006 112.486 0.007
202203 0.000 114.825 0.000
202206 0.000 118.384 0.000
202209 0.000 122.296 0.000
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 0.000 132.205 0.000
202406 0.000 132.716 0.000
202409 0.000 132.304 0.000
202412 0.000 132.987 0.000
202503 0.000 132.825 0.000
202506 0.000 133.699 0.000
202509 0.000 133.480 0.000
202512 0.000 133.390 0.000
202603 0.000 133.560 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Vivesto AB (OASMY) has a Cyclically Adjusted Revenue per Share of $0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivesto AB and its competitors.
Is Vivesto AB's Cyclically Adjusted Revenue per Share too high?
Vivesto AB's current Cyclically Adjusted Revenue per Share is $0.00. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Vivesto AB's Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivesto AB and its competitors. Vivesto AB's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vivesto AB (OASMY), the current Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges VIVE:SwedenOMA:Germany
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score

Get the complete analysis for OASMY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price